基金经理：田希蒙
| 单位净值:1.3106 | 净值增长率:-1.73% | 净值增长率:-1.73% | 累计净值:1.3106 | 截止日期:2026/5/13 | |
|---|---|---|---|---|---|
| 最新估值:-(-) | 涨跌幅:- | 涨跌额:- | |||
| 最新规模:1.51亿元 | 风险等级:高风险 | 申购状态:可申购 | 赎回状态:可赎回 |
展开全部
- 基本资料
- 投资风格
- 基金财务状况
- 基金评级
富国恒生港股通创新药及医疗保健ETF发起式联接A(020110)申购赎回 |
||||||
|---|---|---|---|---|---|---|
| 报告期 | 期初总份额(份) | 期末总份额(份) | 期间总申购份额(份) | 期间总赎回份额(份) | 期间净申赎份额(份) | 净申赎比例 |
| 2026/3/31 | 123,095,000 | 115,501,000 | 60,715,000 | 68,309,500 | -7,594,500 | -6.17% |
| 2025/12/31 | 14,846,200 | 123,095,000 | 306,561,000 | 198,312,000 | 108,249,000 | 729.14% |
| 2025/12/31 | 99,561,800 | 123,095,000 | 61,796,500 | 38,263,100 | 23,533,400 | 23.64% |
| 2025/9/30 | 76,601,900 | 99,561,800 | 130,228,000 | 107,268,000 | 22,960,000 | 29.97% |
| 2025/6/30 | 14,846,200 | 76,601,900 | 114,536,000 | 52,780,200 | 61,755,800 | 415.97% |
| 2025/6/30 | 43,890,600 | 76,601,900 | 77,111,800 | 44,400,500 | 32,711,300 | 74.53% |
| 2025/3/31 | 14,846,200 | 43,890,600 | 37,424,000 | 8,379,640 | 29,044,360 | 195.63% |
| 2024/12/31 | 10,078,800 | 14,846,200 | 14,274,900 | 9,507,480 | 4,767,420 | 47.3% |
| 2024/12/31 | 16,162,800 | 14,846,200 | 2,824,160 | 4,140,690 | -1,316,530 | -8.15% |
| 2024/9/30 | 13,544,600 | 16,162,800 | 4,089,920 | 1,471,790 | 2,618,130 | 19.33% |
| 2024/6/30 | 10,078,800 | 13,544,600 | 7,360,870 | 3,895,000 | 3,465,870 | 34.39% |
| 2024/6/30 | 10,723,900 | 13,544,600 | 6,574,810 | 3,754,100 | 2,820,710 | 26.3% |
| 2024/3/31 | 10,078,800 | 10,723,900 | 786,060 | 140,903 | 645,157 | 6.4% |
*注：新浪财经提醒：以上数据由合作伙伴提供，仅供参考，交易请以正式公告数据为准。